Supplementary Materials



Supplementary Figure S1 Protective effects of DHA and TET pretreatment on EPC cells

A: Changes in SVCV *nucleoprotein* gene expression in cells after DHA and TET pretreatment for 24, 36, and 48 h. B: Cell viability after DHA and TET pretreatment for 8, 16, 24, 36, and 48 h prior to SVCV infection. C: Cell viability at 0, 24, and 48 h after pretreatment with DHA and TET prior to SVCV infection. Each value is mean±SD. *P*-values were determined by Student's *t*-tests. ***P*<0.01; **P*<0.05.



Supplementary Figure S2 Effects of DHA and TET treatment on antiviral-related gene expression in EPC cells

EPC cells were treated with DHA, TET, or the same volume of DMSO. The mRNA levels of *IFN1* (A), *ISG15* (B), *Mx1* (C), *viperin* (D), *MAVS* (E), *RIG-I* (F), *TNF-α* (G), and *IL-1β* (H) were analyzed by qPCR at 24 and 48 h. Each value is mean±SD. *P*-values were determined by Student's *t*-tests. ***P*<0.01; **P*<0.05.

Supplementary Table S1 Sequences of primer pairs used in the present study

Primer		Sequence (5'–3')
SVCV *nucleoprotein*	Forward	AACAGCGCGTCTTACATGC
	Reverse	CTAAGGCGTAAGCCATCAGC
EPC *IFN1*	Forward	ATGAAAACTCAAATGTGGACGTA
	Reverse	GATAGTTTCCACCCATTTCCTTAA
EPC *ISG15*	Forward	GCCTGGTATCACAGACAG
	Reverse	ACATCTTGCACTGACATA
EPC *Mx1*	Forward	ATCTGGTGGATAAGGGAAC
	Reverse	CATCCTCTGTTAATGTGGC
EPC *viperin*	Forward	GCAAAGCGAGGGTTACGAC
	Reverse	CTGCCATTACTAACGATGCTGAC
EPC *MAVS*	Forward	GAATGTCCCTGTCCGAGAAA
	Reverse	TCTGAACATGCTCGTTTGCAG
EPC *RIG-I*	Forward	TGCTGGACCGGATGTGTTATCT
	Reverse	TGGTGATCGATGGTTCGATTCT
EPC *TNF-α*	Forward	TGATGGTGTCGAGGAGGA
	Reverse	CAGGGTCACAGCCAGAAA
EPC *IL-1β*	Forward	CCCAGACCAATCTCTACCTCGCT
	Reverse	GAGGAGGTTGTCATTCTGGTCACC
EPC *β-actin*	Forward	GCTATGTGGCTCTTGACTTCGA
	Reverse	CCGTCAGGCAGCTCATAGCT
ZF *IFNφ*	Forward	GAGCACATGAACTCGGTGAA
	Reverse	TGCGTATCTTGCCACACATT
ZF *ISG15*	Forward	ACTCGGTGGTGATGCTCCTC
	Reverse	CCTTCGGCACTCTCTCTTTC
ZF *Mxab*	Forward	CGCTGTCAGGAGTTCCGTTAC
	Reverse	TTCCGCTGGGTCATCAAAGT
ZF *RIG-I*	Forward	TTGAGGAGCTGCATGAACAC
	Reverse	CCGCTTGAATCTCCTCAGAC
ZF *Ifit13a*	Forward	AGCTCTTCAGCAAGCCTGAC
	Reverse	GAGCCCAGCCTGTACAATTT
ZF *Nrf2*	Forward	AACGAGTTCTCCCTTCAGCA
	Reverse	ATTTTGTCGCCGATTTTGTC
ZF *HO-1*	Forward	GGAAGAGCTGGACAGAAACG
	Reverse	CGAAGAAGTGCTCCAAGTCC
ZF *18S* rRNA	Forward	ACCACCCACAGAATCGAGAAA
	Reverse	GCCTGCGGCTTAATTTGACT